Alaunos Therapeutics Inc
$ 2.22
-0.89%
17 Jun - close price
- Market Cap 5,629,100 USD
- Current Price $ 2.22
- High / Low $ 2.25 / 2.22
- Stock P/E N/A
- Book Value 1.27
- EPS -2.12
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.29 %
- ROE -3.50 %
- 52 Week High 5.48
- 52 Week Low 1.67
About
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
Analyst Target Price
$1.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-02 | 2024-03-05 | 2023-11-14 | 2023-08-14 | 2023-05-10 | 2023-03-07 |
| Reported EPS | -0.55 | -0.63 | -0.67 | -0.4634 | -0.7038 | -0.7051 | -17.09 | -0.49 | -4.41 | -6 | -6 | -0.04 |
| Estimated EPS | 0 | None | None | None | None | None | -4.5 | -0.45 | -5.25 | -6.75 | -6.6 | -0.07 |
| Surprise | -0.55 | 0 | 0 | 0 | 0 | 0 | -12.59 | -0.04 | 0.84 | 0.75 | 0.6 | 0.03 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | -279.7778% | -8.8889% | 16% | 11.1111% | 9.0909% | 42.8571% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TCRT
2026-06-17 20:39:56
Alaunos Therapeutics CEO Holger Weis received a stock grant of 7,761 common shares valued at $2.26 per share on June 12, 2026. This grant was issued in lieu of his net salary, not through an open-market purchase. Following this transaction, Weis directly holds 12,672 shares of Alaunos Therapeutics.
2026-06-17 02:39:39
This article from TradingKey provides an overview of Alaunos Therapeutics Inc (TCRT)'s institutional confidence score, financial data, and shareholder activity. It lists key institutional shareholders and their recent changes in shareholdings, showing that some increased their stakes while others maintained theirs. The institutional confidence score for TCRT is noted as 3.00, remaining unchanged.
2026-06-15 12:39:39
This article provides a risk assessment for Alaunos Therapeutics Inc (TCRT), detailing its volatility, financial risk, and investment risk. It highlights the company's beta value of -1.06, indicating it tends to underperform in rising markets but declines less in falling ones. The report also includes various metrics such as VaR, maximum drawdown, Sharpe Ratio, and daily return/loss percentages over different periods.
2026-05-27 20:39:23
Alaunos Therapeutics (TCRT) CEO Holger Weis received 3,700 shares of common stock at $2.37 per share on May 22, 2026, as compensation in lieu of his net salary. Following this transaction, Weis directly holds 4,911 shares of Alaunos common stock. This insider activity was reported via a Form 4 filing, indicating an award rather than a market purchase or sale.
2026-05-27 17:39:23
Alaunos Biomedical announced positive preclinical results for its new obesity drug, which demonstrated significant reductions in body weight, improved liver health, and enhanced insulin sensitivity in animal models. These findings suggest the drug could be a promising candidate for treating obesity and related metabolic disorders. Further research and clinical trials are anticipated to validate these early results.
2026-05-26 17:10:24
Alaunos Therapeutics has released integrated preclinical data for its oral obesity drug candidate, ALN1003, showing significant body weight and liver weight reductions in diet-induced obesity mouse studies. Despite these promising results and potential benefits for metabolic issues, the company faces significant financial challenges, including a precarious cash position and non-compliance with Nasdaq's equity rule. ALN1003 has not yet been evaluated in human clinical trials, and the company plans further preclinical studies and seeks additional financing.
